Breaking News Instant updates and real-time market news.

AGN

Allergan

$165.16

35.51 (27.39%)

, MNK

Mallinckrodt

$8.48

0.06 (0.71%)

09:55
06/25/19
06/25
09:55
06/25/19
09:55

Early notable gainers among liquid option names on June 25th

Notable gainers among liquid option names this morning include Allergan (AGN) $165.27 +35.78, Mallinckrodt (MNK) $8.74 +0.31, Mylan (MYL) $18.53 +0.57, Biogen (BIIB) $241.96 +6.08, and ConAgra (CAG) $28.76 +0.64.

AGN

Allergan

$165.16

35.51 (27.39%)

MNK

Mallinckrodt

$8.48

0.06 (0.71%)

MYL

Mylan

$18.16

0.2 (1.11%)

BIIB

Biogen

$239.70

3.81 (1.62%)

CAG

Conagra Brands

$28.53

0.42 (1.49%)

  • 25

    Jun

  • 27

    Jun

  • 23

    Jul

AGN Allergan
$165.16

35.51 (27.39%)

06/25/19
MZHO
06/25/19
NO CHANGE
Target $171
MZHO
Buy
Allergan price target lowered to $171 from $194 at Mizuho
Mizuho analyst Irina Koffler lowered her Botox Cosmetic and CoolSculpt estimates after conducting a survey of 20 dermatologists and plastic surgeons, who gave the impression that that the Botox franchise will be pressured by Evolus (EOLS) and other new entrants. Koffler cut her price target on Allergan shares to $171 from $194 based on the lowered estimates, but maintains a Buy rating on the stock, stating that it is "widely expected" that the company will make a strategic announcement that begins the preliminary work of separating the company in the next 1-2 months.
06/25/19
PIPR
06/25/19
NO CHANGE
PIPR
Neutral
Piper says 'willing to listen' to AbbVie reasoning for Allergan acquisition
Ahead of the call to discuss AbbVie's (ABBV) planned $63B acquisition of Allergan (AGN), Piper Jaffray analyst Christopher Raymond said his first reaction to the deal could be summed up with the phrase "two turkeys don't make an eagle," but he is "willing to listen" despite his skepticism about the transaction. Though he cannot say he is "excited at the prospect of AbbVie entering the field of medical aesthetics," EPS accretion of 10% in year one and over 20% at peak, and the potential for meaningful deleveraging and cost cutting, has his attention, Raymond said. He keeps a Neutral rating on AbbVie based on his initial reaction to the deal announcement.
06/25/19
WELS
06/25/19
NO CHANGE
WELS
Outperform
Deals with premiums like Allergan's 'rarely killed,' says Wells Fargo
After Abbvie (ABBV) announced an agreement to acquire Allergan (AGN) for $120 per share of cash and a remaining $68 in AbbVie shares, Wells Fargo analyst David Maris said he views the deal as a good alternative for Allergan versus the current share price, but he is not convinced its a better long term alternative given the eventual biosimilar threat to Abbvie's blockbuster drug Humira. With that said, Maris tells investors that "deals at such premiums are rarely killed because of a bad strategic fit or longer -term value outlook in the absence of other bidders." Though he would not completely rule out an activist investor disrupting the deal, he thinks it is unlikely given there has been a strategic review of the company for some time. Maris, who said he thinks the deal could go through, keeps an Outperform rating on Allergan shares.
06/25/19
LEER
06/25/19
NO CHANGE
LEER
Outperform
Bid of $188 for Allergan 'too low,' others may pursue as well, says SVB Leerink
SVB Leerink analyst Marc Goodman is not surprise that one of the large pharma companies has made a bid on Allergan (AGN) given the multi-year stock weakness. However, he believes a $188 price is "too low," as he "can't believe that Allergan is not being taken out at least at $200," which "begs the question" whether this was a process or is AbbVie (ABBV) "opportunistically pursuing a wounded stock." If it is the latter, Goodman believes this bid could initiate others to pursue Allergan as well. He has an Outperform rating on Allegan's shares.
MNK Mallinckrodt
$8.48

0.06 (0.71%)

06/11/19
LEHM
06/11/19
INITIATION
Target $11
LEHM
Equal Weight
Mallinckrodt initiated with an Equal Weight at Barclays
Barclays analyst Balaji Prasad started Mallinckrodt with an Equal Weight rating and $11 price target. The analyst launched coverage of 20 U.S. Specialty Pharmaceuticals with a Neutral industry view. He placed importance on cash flows and companies' ability to manage leverage and improve balance sheets.
06/12/19
CANT
06/12/19
NO CHANGE
Target $18
CANT
Overweight
Mallinckrodt price target lowered to $18 from $42 at Cantor Fitzgerald
Cantor Fitzgerald analyst Louise Chen lowered her price target for Mallinckrodt to $18 from $42, driven by multiple contraction, given increasing headwinds from macro factors. While acknowledging that competition for Acthar could drive downside to her estimates and the consensus, the analyst reiterates an Overweight rating on the shares.
06/13/19
STFL
06/13/19
NO CHANGE
Target $24
STFL
Hold
Mallinckrodt's Acthar Phase 4 data shows 'strong' evidence in RA, says Stifel
Stifel analyst Annabel Samimy maintained a Hold rating and $24 price target on Mallinckrodt after the company released the full release of its two-part Phase 4 study of Acthar in refractory patients with persistent Rheumatoid Arthritis at EULAR, noting that both parts of the study hit all primary and secondary endpoints. In a research note to investors, Samimy says with these data that show "strong" clinical evidence in RA, she sees opportunity for Mallinckrodt to have more meaningful clinical discussions in third-party payer negotiations and greater validation with Medicare, both of which could support Acthar volumes going forward.
06/14/19
ADAM
06/14/19
NO CHANGE
Target $22
ADAM
Buy
Mallinckrodt price target lowered to $22 from $37 at Canaccord
Canaccord analyst Dewey Steadman lowered his price target on Mallinckrodt to $22 from $37 following the company's release of a blinded RA study showing Acthar's effectiveness. The analyst noted the data is the first of a string of expected Acthar data reads that he thinks can bolster and justify Acthar's use for exacerbations in highly refractory immune-modulated conditions. The price target reduction is based on a lower expected contribution from pipeline products. Steadman maintained his Buy rating on Mallinckrodt shares.
MYL Mylan
$18.16

0.2 (1.11%)

06/11/19
LEHM
06/11/19
INITIATION
Target $26
LEHM
Overweight
Mylan initiated with an Overweight at Barclays
Barclays analyst Balaji Prasad started Mylan with an Overweight rating and $26 price target. The analyst launched coverage of 20 U.S. Specialty Pharmaceuticals with a Neutral industry view. He placed importance on cash flows and companies' ability to manage leverage and improve balance sheets.
05/30/19
WELS
05/30/19
NO CHANGE
WELS
U.S. generic data continues to show challenging environment, says Wells Fargo
Wells Fargo analyst David Maris says that according to April IQVIA data, Teva (TEVA) U.S. generic sales were down 19% in April year over year, while brands sales were down 15%. Additionally, according to IQVIA data, Teva recently ceded its second place U.S. prescription market share place to competitor Eli Lilly (LLY) for its migraine drug, Ajovy, he points out. For Mylan (MYL), Maris says the monthly trends also paint a negative picture, with IQVIA U.S. generic sales in April down 36%. Nonetheless, the analyst believes Teva and Mylan shares seem to be reflecting an "aggressively negative outlook" given the current earnings multiples, and setting aside the worst-case outcomes in the opioid and price fixing cases, these may be at or nearing attractive valuations. However, for now, he remains on the sidelines, and within generics, continues to recommend Outperform-rated Amphastar (AMPH).
05/29/19
WELS
05/29/19
NO CHANGE
Target $188
WELS
Outperform
Allergan selloff on opioid concerns an overreaction, says Wells Fargo
Wells Fargo analyst David Maris attributes the 5% selloff today in shares of Allergan (AGN) to heightened fears of opioid liability risks in the sector. Maris spoke to Allergan's investor relations team, which noted the company is fully indemnified regarding legacy Actavis generics issues. Further, Allergan has very little exposure to branded opioid sales, as they represent a very small percentage of the company's branded business, Maris tells investors in a research note. He believes the decline in Allergan shares is an overreaction to the negative headlines related to opioid-based litigation facing a number of specialty pharma companies such as Teva (TEVA), Mylan (MYL), and Mallinckrodt (MNK). Maris calls the selloff overdone and recommends buying shares of Allergan. He keeps an Outperform rating on the name with a $188 price target.
06/12/19
CANT
06/12/19
NO CHANGE
Target $18
CANT
Neutral
Mylan price target lowered to $18 from $31 at Cantor Fitzgerald
Cantor Fitzgerald analyst Louise Chen lowered her price target for Mylan to $18 from $31, driven by multiple contraction, given increasing headwinds from macro factors. The analyst reiterates a Neutral rating on the shares.
BIIB Biogen
$239.70

3.81 (1.62%)

06/05/19
STPT
06/05/19
UPGRADE
STPT
Buy
Biogen upgraded to Buy from Hold at Standpoint Research
05/22/19
05/22/19
UPGRADE

Citi assumes coverage of large-cap biotech, upgrades Amgen and Gilead
Citi analyst Mohit Bansal assumed coverage of large-cap biotech stocks, assuming coverage with five Buy ratings -- Amgen (AMGN), Alexion Pharmaceuticals (ALXN), Vertex Pharmaceuticals (VRTX), Gilead Sciences (GILD), and BioMarin Pharmaceutical (BMRN) -- and two Neutral ratings -- Biogen (BIIB) and Regeneron Pharmaceuticals (REGN). Both Amgen and Gilead were upgraded to Buy from Neutral as part of the assumption of coverage. The analyst said he is "more optimistic" on the sector as a whole as he sees many biotechs going "back to basics" by investing in their internal pipelines and filling their pipelines with early stage assets. He suggests looking at large caps again, as many are returning to stability and growth. Bansal does not favor large M&A, suggesting discipline due to "realizing value with big M&As."
05/23/19
05/23/19
INITIATION
Target $231

Neutral
Biogen initiated with a Neutral at Wedbush
As previously reported, Wedbush analyst Laura Chico started Biogen with a Neutral rating and a $231 price target. The analyst says the company is "at a crossroads" as it looks to move on from its recent aducanumab Alzheimer's disease setback, noting that few of its early-stage pipeline assets appear to be positioned to make a near-term impact on its top line. Chico further warns that inter partes review of Biogen's Tecfidera patent could lead to generic competition sooner than expected.
05/24/19
FBCO
05/24/19
NO CHANGE
FBCO
Underperform
Zolgensma label breadth on higher end of expectations, says Credit Suisse
Credit Suisse analyst Evan Seigerman noted that the FDA announced approval for Novartis' (NVS) Zolgensma for the treatment of Spinal Muscular Atrophy, or SMA, in patients with bi-allelic mutations in the SMN1 gene under 2 years of age. The current wholesale acquisition cost for Biogen's (BIIB) Spinraza equates to a per-year treatment cost of $500,000 for the first year loading phase and $250,000-$375,000 per year for maintenance thereafter, which compares to a WAC of $2.125M for Zolgensma, which is administered just once, noted Seigerman. While investors generally expected Zolgensma would be approved, the breadth of the label was on the higher end of expectations, Seigerman tells investors. The pricing and label support his below consensus view of Spinraza, as he continues to expect that Zolgensma will become the preferred first option for infant-onset type 1 SMA, said the analyst, who reiterates his $198 price target and Underperform rating on Biogen shares.
CAG Conagra Brands
$28.53

0.42 (1.49%)

04/11/19
JPMS
04/11/19
NO CHANGE
Target $34
JPMS
Overweight
JPMorgan sees 'much more upside' in Conagra, boosts target to $34
JPMorgan analyst Ken Goldman raised his price target for Conagra Brands to $34 from $30 saying he sees "much more upside" in the shares. The company's longer-term sales guidance seems conservative and beatable, Goldman tells investors in a research note. He also believes management is addressing a number of investor concerns, including the sustainability of the frozen category's strength, the reasons for reductions in A&P spending, and the plan to turn around Pinnacle. Goldman reiterates an Overweight rating on Conagra Brands.
06/11/19
EVER
06/11/19
INITIATION
Target $36
EVER
Outperform
Conagra Brands initiated with an Outperform at Evercore ISI
Evercore ISI analyst David Palmer started Conagra Brands with an Outperform rating and $36 price target.
05/14/19
RHCO
05/14/19
INITIATION
Target $35
RHCO
Buy
Conagra Brands initiated with a Buy at SunTrust
SunTrust analyst William Chappell initiated Conagra Brands with a Buy rating and a price target of $35, saying the arrival of new management and its efforts to implement a "scalable, repeatable process" across the organization has led to growth in all of its business units. The analyst also sees signs of stabilization for packaged foods companies generally after a "challenging" few years amid a shift toward more favorable pricing and increased demographic tailwinds for frozen foods as more Millenials have children.
05/20/19
MSCO
05/20/19
INITIATION
Target $31
MSCO
Equal Weight
Conagra Brands resumed with an Equal Weight at Morgan Stanley
Morgan Stanley analyst Pamela Kaufman resumed coverage of Conagra Brands with an Equal Weight rating and $31 price target. While she believes the company is well-positioned for revenue growth ahead of Packaged Food peers, she still sees risk with the turnaround of Pinnacle Foods and thinks the risk-reward appears balanced given recently rising expectations.

TODAY'S FREE FLY STORIES

12:45
07/19/19
07/19
12:45
07/19/19
12:45
General news
Breaking General news story  »

Week of 7/19 Baker-Hughes…

LYFT

Lyft

$67.78

1.74 (2.63%)

12:43
07/19/19
07/19
12:43
07/19/19
12:43
Hot Stocks
Lyft announces new airport pickup feature starting July 20 at LGA »

In a blog post, Lyft…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Aug

  • 08

    Aug

WMT

Walmart

$114.81

0.13 (0.11%)

12:41
07/19/19
07/19
12:41
07/19/19
12:41
Periodicals
Walmart to shuffle executives to further integrate stores and digital, CNBC says »

Walmart is shuffling its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Aug

  • 25

    Sep

  • 13

    Nov

WMT

Walmart

$114.83

0.15 (0.13%)

12:36
07/19/19
07/19
12:36
07/19/19
12:36
Periodicals
Walmart to shuffle executives to further integrate stores and digital, CNBC says »

CNBC's Courtney…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Aug

  • 25

    Sep

  • 13

    Nov

NFLX

Netflix

$321.59

-3.55 (-1.09%)

12:29
07/19/19
07/19
12:29
07/19/19
12:29
Periodicals
Eddie Murphy in talks with Netflix over comedy specials, TMZ reports »

Comedian and actor Eddie…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Aug

FL

Foot Locker

$42.72

0.35 (0.83%)

12:25
07/19/19
07/19
12:25
07/19/19
12:25
Options
Foot Locker call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Aug

  • 19

    Sep

  • 25

    Sep

DIS

Disney

$141.00

-0.62 (-0.44%)

, SNE

Sony

$53.93

-0.02 (-0.04%)

12:21
07/19/19
07/19
12:21
07/19/19
12:21
On The Fly
Box Office Battle: 'Lion King' expected to claim this weekend's throne »

Welcome to "Box Office…

DIS

Disney

$141.00

-0.62 (-0.44%)

SNE

Sony

$53.93

-0.02 (-0.04%)

T

AT&T

$32.91

-0.185 (-0.56%)

CBS

CBS

$51.32

-0.02 (-0.04%)

CMCSA

Comcast

$44.14

-0.42 (-0.94%)

CMCSK

Comcast

$0.00

(0.00%)

LGF.A

Lionsgate

$11.72

0.14 (1.21%)

LGF.B

Lionsgate

$11.05

0.03 (0.27%)

VIA

Viacom

$35.39

0.39 (1.11%)

VIAB

Viacom

$30.79

0.2 (0.65%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

  • 25

    Jul

  • 30

    Jul

  • 30

    Jul

  • 06

    Aug

  • 08

    Aug

  • 08

    Aug

  • 08

    Aug

  • 08

    Aug

  • 08

    Aug

  • 08

    Aug

12:21
07/19/19
07/19
12:21
07/19/19
12:21
Conference/Events
Wolfe Research utilities/midstream analyst to hold a group luncheon »

Utilities & Midstream…

AMRX

Amneal Pharmaceuticals

$3.35

-0.04 (-1.18%)

, BMY

Bristol-Myers

$43.57

-0.47 (-1.07%)

12:18
07/19/19
07/19
12:18
07/19/19
12:18
Hot Stocks
Amneal Pharmaceuticals granted tentative FDA approval of Apremilast »

Amneal Pharmaceuticals…

AMRX

Amneal Pharmaceuticals

$3.35

-0.04 (-1.18%)

BMY

Bristol-Myers

$43.57

-0.47 (-1.07%)

CELG

Celgene

$90.39

-0.51 (-0.56%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jul

  • 25

    Jul

  • 08

    Aug

  • 03

    Sep

  • 16

    Sep

  • 04

    Dec

  • 25

    Mar

  • 04

    Apr

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

12:17
07/19/19
07/19
12:17
07/19/19
12:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

12:16
07/19/19
07/19
12:16
07/19/19
12:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

YGTY

SSLJ.com

$1.18

-0.12 (-9.23%)

12:15
07/19/19
07/19
12:15
07/19/19
12:15
Hot Stocks
Breaking Hot Stocks news story on SSLJ.com »

SSLJ com Ltd (Class A…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BA

Boeing

$374.39

13.22 (3.66%)

, MSFT

Microsoft

$138.27

1.98 (1.45%)

12:10
07/19/19
07/19
12:10
07/19/19
12:10
On The Fly
Fly Intel: Wall Street's top stories at midday »

Stocks are modestly…

BA

Boeing

$374.39

13.22 (3.66%)

MSFT

Microsoft

$138.27

1.98 (1.45%)

AXP

American Express

$125.00

-3.4 (-2.65%)

GCI

Gannett

$9.62

1.72 (21.77%)

CRWD

Crowdstrike

$83.30

10.55 (14.50%)

SKX

Skechers

$39.35

4.6 (13.24%)

MIK

Michaels

$7.75

-0.62 (-7.41%)

PACB

Pacific Biosciences

$5.23

-0.64 (-10.90%)

ILMN

Illumina

$291.57

-6.97 (-2.33%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jul

  • 24

    Jul

  • 29

    Jul

  • 03

    Aug

  • 06

    Aug

  • 08

    Aug

  • 03

    Sep

  • 25

    Sep

  • 13

    Nov

CMI

Cummins

$170.04

2.08 (1.24%)

, VWAGY

Volkswagen

$0.00

(0.00%)

12:06
07/19/19
07/19
12:06
07/19/19
12:06
Periodicals
Cummins makes bid for VW's MAN Energy Solutions unit, Reuters says »

Cummins (CMI) has made an…

CMI

Cummins

$170.04

2.08 (1.24%)

VWAGY

Volkswagen

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jul

  • 06

    Aug

SSRM

SSR Mining

$15.69

-0.04 (-0.25%)

12:05
07/19/19
07/19
12:05
07/19/19
12:05
Options
SSR Mining call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Aug

12:05
07/19/19
07/19
12:05
07/19/19
12:05
General news
U.S. Data Slate: The week of July 22 »

U.S. Data Slate: The week…

XOM

Exxon Mobil

$74.86

0.02 (0.03%)

12:04
07/19/19
07/19
12:04
07/19/19
12:04
Periodicals
Exxon Mobil starts process of selling Norwegian oil fields, Bloomberg says »

Exxon Mobil has begun the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Aug

CTK

CooTek

$8.54

-0.02 (-0.23%)

12:00
07/19/19
07/19
12:00
07/19/19
12:00
Hot Stocks
CooTek falls -6.6% »

CooTek is down -6.6%, or…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CHWY

Chewy

$30.63

-2.16 (-6.59%)

12:00
07/19/19
07/19
12:00
07/19/19
12:00
Hot Stocks
Chewy falls -6.8% »

Chewy is down -6.8%, or…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

QEP

QEP Resources

$5.29

-1.02 (-16.16%)

12:00
07/19/19
07/19
12:00
07/19/19
12:00
Hot Stocks
QEP Resources falls -16.2% »

QEP Resources is down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SKX

Skechers

$39.22

4.47 (12.86%)

12:00
07/19/19
07/19
12:00
07/19/19
12:00
Hot Stocks
Skechers rises 12.6% »

Skechers is up 12.6%, or…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IFS

Intercorp Financial Services

$45.32

(0.00%)

12:00
07/19/19
07/19
12:00
07/19/19
12:00
Hot Stocks
Intercorp Financial Services rises 17.6% »

Intercorp Financial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jul

GCI

Gannett

$9.55

1.65 (20.89%)

12:00
07/19/19
07/19
12:00
07/19/19
12:00
Hot Stocks
Gannett rises 21.1% »

Gannett is up 21.1%, or…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PM

Philip Morris

$89.57

1.92 (2.19%)

, NWSA

News Corp.

$13.21

-0.075 (-0.56%)

11:58
07/19/19
07/19
11:58
07/19/19
11:58
On The Fly
Downgrades of News Corp., Alcoa among today's top analyst calls »

Check out today's top…

PM

Philip Morris

$89.57

1.92 (2.19%)

NWSA

News Corp.

$13.21

-0.075 (-0.56%)

MSGN

MSG Networks

$19.70

-0.52 (-2.57%)

AA

Alcoa

$23.31

-0.11 (-0.47%)

MIK

Michaels

$7.73

-0.64 (-7.65%)

BA

Boeing

$373.56

12.39 (3.43%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

  • 25

    Sep

  • 16

    Oct

RCUS

Arcus Biosciences

$8.31

-0.21 (-2.46%)

11:49
07/19/19
07/19
11:49
07/19/19
11:49
Conference/Events
Arcus Biosciences management to meet with Wedbush »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

  • 25

    Jul

  • 09

    Sep

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.